Peripheral Defocus, Pupil Size, and Axial Eye Growth in Children Wearing Soft Multifocal Contact Lenses in the BLINK Study.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 11 2023
Historique:
medline: 2 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

The purpose of this study was to evaluate the relationship between peripheral defocus and pupil size on axial growth in children randomly assigned to wear either single vision contact lenses, +1.50 diopter (D), or +2.50 D addition multifocal contact lenses (MFCLs). Children 7 to 11 years old with myopia (-0.75 to -5.00 D; spherical component) and ≤1.00 D astigmatism were enrolled. Autorefraction (horizontal meridian; right eye) was measured annually wearing contact lenses centrally and ±20 degrees, ±30 degrees, and ±40 degrees from the line of sight at near and distance. Photopic and mesopic pupil size were measured. The effects of peripheral defocus, treatment group, and pupil size on the 3-year change in axial length were modeled using multiple variables that evaluated defocus across the retina. Although several peripheral defocus variables were associated with slower axial growth with MFCLs, they were either no longer significant or not meaningfully associated with eye growth after the treatment group was included in the model. The treatment group assignment better explained the slower eye growth with +2.50 MFCLs than peripheral defocus. Photopic and mesopic pupil size did not modify eye growth with the +2.50 MFCL (all P ≥ 0.37). The optical signal causing slower axial elongation with +2.50 MFCLs is better explained by the lens type worn than by peripheral defocus. The signal might be something other than peripheral defocus, or there is not a linear dose-response relationship within treatment groups. We found no evidence to support pupil size as a criterion when deciding which myopic children to treat with MFCLs.

Identifiants

pubmed: 37910092
pii: 2792971
doi: 10.1167/iovs.64.14.3
pmc: PMC10627291
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3

Subventions

Organisme : NEI NIH HHS
ID : P30 EY007551
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002733
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023204
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023208
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023206
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023210
Pays : United States

Références

Invest Ophthalmol Vis Sci. 2022 Sep 1;63(10):17
pubmed: 36169949
Vision Res. 2001 Feb;41(3):267-73
pubmed: 11164443
Cont Lens Anterior Eye. 2015 Feb;38(1):2-14
pubmed: 25139719
Br J Ophthalmol. 2014 Jan;98(1):40-5
pubmed: 24169657
Vision Res. 2009 Sep;49(19):2386-92
pubmed: 19632261
Ophthalmic Physiol Opt. 1999 Mar;19(2):126-33
pubmed: 10615448
Nat Med. 1995 Aug;1(8):761-5
pubmed: 7585177
Invest Ophthalmol Vis Sci. 2011 Dec 09;52(13):9362-7
pubmed: 22039230
Vision Res. 1995 Jan;35(1):37-50
pubmed: 7839608
Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5761-70
pubmed: 23838771
Vision Res. 2009 Jan;49(2):219-27
pubmed: 18992765
Eye Contact Lens. 2018 Jul;44(4):260-267
pubmed: 27763910
Cont Lens Anterior Eye. 2023 Feb;46(1):101723
pubmed: 35654683
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500
pubmed: 12657584
Optom Vis Sci. 2012 Nov;89(11):1636-40
pubmed: 23026791
Optom Vis Sci. 2013 Jun;90(6):530-9
pubmed: 23645372
Ophthalmic Physiol Opt. 2018 May;38(3):326-336
pubmed: 29691930
Optom Vis Sci. 2013 Nov;90(11):1225-36
pubmed: 24037063
Vision Res. 2011 May 11;51(9):1039-46
pubmed: 21342658
Optom Vis Sci. 2009 May;86(5):429-46
pubmed: 19342977
Optom Vis Sci. 2013 Jul;90(7):658-66
pubmed: 23748848
Optom Vis Sci. 2014 Jun;91(6):642-9
pubmed: 24811847
Invest Ophthalmol Vis Sci. 2000 May;41(6):1259-69
pubmed: 10798639
JAMA Ophthalmol. 2022 May 1;140(5):472-478
pubmed: 35357402
Ophthalmic Physiol Opt. 2021 Mar;41(2):393-400
pubmed: 33295033
Ophthalmic Physiol Opt. 2005 Sep;25(5):381-91
pubmed: 16101943
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):3864-73
pubmed: 20220051
Science. 1987 Jul 3;237(4810):73-7
pubmed: 3603011
Optom Vis Sci. 2017 Sep;94(9):856-866
pubmed: 28737608
JAMA. 2020 Aug 11;324(6):571-580
pubmed: 32780139
Optom Vis Sci. 2011 May;88(5):E570-9
pubmed: 21317668
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4514-9
pubmed: 26200489
Prog Retin Eye Res. 2021 Jul;83:100923
pubmed: 33253901
Prog Retin Eye Res. 2012 Nov;31(6):622-60
pubmed: 22772022
Optom Vis Sci. 2019 Aug;96(8):556-567
pubmed: 31343513
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Ophthalmic Physiol Opt. 2008 Jan;28(1):57-61
pubmed: 18201336
Optom Vis Sci. 2017 Mar;94(3):370-379
pubmed: 28225372
Br J Ophthalmol. 2018 Jul;102(7):855-862
pubmed: 29699985
Ophthalmic Physiol Opt. 2020 Nov;40(6):728-737
pubmed: 32888318
Optom Vis Sci. 2013 Nov;90(11):1215-24
pubmed: 24076542
Optom Vis Sci. 1997 Jun;74(6):367-75
pubmed: 9255814
Exp Eye Res. 2013 Sep;114:77-88
pubmed: 23290590
Invest Ophthalmol Vis Sci. 2012 Oct 11;53(11):7077-85
pubmed: 22969068
Ophthalmology. 2019 Mar;126(3):338-346
pubmed: 30342076
Optom Vis Sci. 2021 Aug 1;98(8):983-994
pubmed: 34393205
Optom Vis Sci. 2022 May 1;99(5):434-442
pubmed: 35511120
Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2143-51
pubmed: 15223788
Vision Res. 1988;28(5):639-57
pubmed: 3195068
Optom Vis Sci. 2011 Apr;88(4):476-82
pubmed: 21317669
Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):640-9
pubmed: 22205604
Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1647-59
pubmed: 15161822

Auteurs

David A Berntsen (DA)

College of Optometry, The University of Houston, Houston, Texas, United States.

Anita Ticak (A)

College of Optometry, The University of Houston, Houston, Texas, United States.

Loraine T Sinnott (LT)

College of Optometry, The Ohio State University, Columbus, Ohio, United States.

Moriah A Chandler (MA)

College of Optometry, The University of Houston, Houston, Texas, United States.

Jenny Huang Jones (JH)

College of Optometry, The Ohio State University, Columbus, Ohio, United States.

Ann Morrison (A)

College of Optometry, The Ohio State University, Columbus, Ohio, United States.

Lisa A Jones-Jordan (LA)

College of Optometry, The Ohio State University, Columbus, Ohio, United States.

Jeffrey J Walline (JJ)

College of Optometry, The Ohio State University, Columbus, Ohio, United States.

Donald O Mutti (DO)

College of Optometry, The Ohio State University, Columbus, Ohio, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH